Ann: Results of Phase 2 Clinical Trial, page-152

Could also possibly add the comorbidity and racial aspects , age or drug interactions ( even herbal that USA are hooked on)  as well  in comparisons to other studies.  Mobility is a major in wound care as better health may lead to better mobility  leading to better circulation and quicker recovery etc. . Small companies also lose as they after a failure don't have time or cash to delve and reprocess data as they effectively don't have The funding .  Large companies use that database to design and compare future trials with all the extra details.  . S&N would love full access to raw data to run against their datasets and pick anomalys as it will save them in their next trial of something.  It is a shame in science all failed trials are not published and accessible in full so others can get value from the database and save on research development cost.   Maybe govt should enforce it against rebate and a small equity in successful products from trials..